First Delayed Resection Findings After Irreversible Electroporation (IRE) of Human Localised Renal Cell Carcinoma (RCC) in the IRENE Pilot Phase 2a Trial

被引：0
|
作者：
Johann Jakob Wendler
Jens Ricke
Maciej Pech
Frank Fischbach
Julian Jürgens
Sandra Siedentopf
Albert Roessner
Markus Porsch
Daniel Baumunk
Martin Schostak
Jens Köllermann
Uwe-Bernd Liehr
机构：
[1] Otto von Guericke University of Magdeburg,Department of Urology, University Hospital
[2] Sana Klinikum Offenbach Am Main,Institute of Pathology
[3] University of Magdeburg,Department of Radiology
[4] University of Magdeburg,Institute of Pathology
来源：
CardioVascular and Interventional Radiology | 2016年 / 39卷
关键词：
Irreversible electroporation (IRE); Renal cell carcinoma (RCC); Small renal mass (SRM); Kidney; Focal therapy (FT); Ablation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：239 / 250
页数：11
相关论文
共 20 条
  • [1] First Delayed Resection Findings After Irreversible Electroporation (IRE) of Human Localised Renal Cell Carcinoma (RCC) in the IRENE Pilot Phase 2a Trial
    Wendler, Johann Jakob
    Ricke, Jens
    Pech, Maciej
    Fischbach, Frank
    Juergens, Julian
    Siedentopf, Sandra
    Roessner, Albert
    Porsch, Markus
    Baumunk, Daniel
    Schostak, Martin
    Koellermann, Jens
    Liehr, Uwe-Bernd
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2016, 39 (02) : 239 - 250
  • [2] A prospective Phase 2a pilot study investigating focal percutaneous irreversible electroporation (IRE) ablation by NanoKnife in patients with localised renal cell carcinoma (RCC) with delayed interval tumour resection (IRENE trial)
    Wendler, J. J.
    Porsch, M.
    Nitschke, S.
    Koellermann, J.
    Siedentopf, S.
    Pech, M.
    Fischbach, F.
    Ricke, J.
    Schostak, M.
    Liehr, U. B.
    CONTEMPORARY CLINICAL TRIALS, 2015, 43 : 10 - 19
  • [3] Upper-Urinary-Tract Effects After Irreversible Electroporation (IRE) of Human Localised Renal-Cell Carcinoma (RCC) in the IRENE Pilot Phase 2a Ablate-and-Resect Study
    Wendler, J. J.
    Pech, M.
    Koellermann, J.
    Friebe, B.
    Siedentopf, S.
    Blaschke, S.
    Schindele, D.
    Porsch, M.
    Baumunk, D.
    Juergens, J.
    Fischbach, F.
    Ricke, J.
    Schostak, M.
    Boehm, M.
    Liehr, U. B.
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2018, 41 (03) : 466 - 476
  • [4] Upper-Urinary-Tract Effects After Irreversible Electroporation (IRE) of Human Localised Renal-Cell Carcinoma (RCC) in the IRENE Pilot Phase 2a Ablate-and-Resect Study
    J. J. Wendler
    M. Pech
    J. Köllermann
    B. Friebe
    S. Siedentopf
    S. Blaschke
    D. Schindele
    M. Porsch
    D. Baumunk
    J. Jürgens
    F. Fischbach
    J. Ricke
    M. Schostak
    M. Böhm
    U. B. Liehr
    CardioVascular and Interventional Radiology, 2018, 41 : 466 - 476
  • [5] Initial Assessment of the Efficacy of Irreversible Electroporation in the Focal Treatment of Localized Renal Cell Carcinoma With Delayed-interval Kidney Tumor Resection (Irreversible Electroporation of Kidney Tumors Before Partial Nephrectomy [IRENE] Trial-An Ablate-and-Resect Pilot Study)
    Wendler, Johann J.
    Pech, Maciej
    Fischbach, Frank
    Juergens, Julian
    Friebe, Bjorn
    Baumunk, Daniel
    Porsch, Markus
    Blaschke, Simon
    Schindele, Daniel
    Siedentopf, Sandra
    Ricke, Jens
    Schostak, Martin
    Koellermann, Jens
    Liehr, Uwe B.
    UROLOGY, 2018, 114 : 224 - 232
  • [6] A randomized, open label, multicenter phase 2 study to evaluate the efficacy of sorafenib in patients (pts) with advanced renal cell carcinoma (RCC) after radical resection of metastases: RESORT trial
    Procopio, Giuseppe
    Grassi, Paolo
    Cognetti, Francesco
    Milella, Michele
    Mosca, Alessandra
    Chiuri, Vincenzo Emanuele
    Ortega, Cinzia
    Passalacqua, Rodolfo
    Bearz, Alessandra
    Morelli, Franco
    Atzori, Francesco
    Montone, Rosanna
    Mennitto, Alessia
    Ratta, Raffaele
    De Braud, Filippo G.
    Verzoni, Elena
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Biomarkers before and after nephrectomy of locally advanced or metastatic renal cell carcinoma (RCC) treated with everolimus: Neorad phase 2 trial (PREDICT consortium)
    Oudard, S.
    Mejean, A.
    Topart, D.
    Thuret, R.
    Tournigand, C.
    Salomon, L.
    Thiery-Vuillemin, A.
    Guichard, G.
    Le Moulec, S.
    Houlgatte, A.
    Guillot, A.
    Mottet, N.
    Cessot, A.
    Barry-Delongchamps, N.
    Elaidi, R.
    Turajlic, S.
    Swanton, C.
    Escudier, B.
    Patard, J. J.
    Albiges, L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [8] A randomized, open label, multicenter phase 2 study to evaluate the efficacy of sorafenib in patients (pts) with advanced Renal Cell Carcinoma (RCC) after a radical resection of the metastases.
    Verzoni, Elena
    Grassi, Paolo
    Montone, Rosanna
    Maggi, Claudia
    Cognetti, Francesco
    Milella, Michele
    Bearz, Alessandra
    Ortega, Cinzia
    Morelli, Franco
    Chiuri, Vincenzo Emanuele
    Necchi, Andrea
    De Braud, Filippo G.
    Procopio, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN
    Melichar, B.
    Bracarda, S.
    Matveev, V.
    Alekseev, B.
    Ivanov, S.
    Zyryanov, A.
    Janciauskiene, R.
    Fernebro, E.
    Mulders, P.
    Osborne, S.
    Jethwa, S.
    Mickisch, G.
    Gore, M.
    van Moorselaar, R. J. A.
    Staehler, M.
    Magne, N.
    Bellmunt, J.
    ANNALS OF ONCOLOGY, 2013, 24 (09) : 2396 - 2402
  • [10] Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-α2a for patients with advanced renal cell carcinoma
    Motzer, RJ
    Rakhit, A
    Thompson, JA
    Nemunaitis, J
    Murphy, BA
    Ellerhorst, J
    Schwartz, LH
    Berg, WJ
    Bukowski, RM
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2001, 21 (04): : 257 - 263
12